Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
La
CAS Number:
Molecular Weight:
138.91
NACRES:
NA.23
PubChem Substance ID:
UNSPSC Code:
12141607
MDL number:
Product Name
Lanthanum, foil, 25x25mm, thickness 0.125mm, as rolled, 99%
InChI
1S/La
SMILES string
[La]
InChI key
FZLIPJUXYLNCLC-UHFFFAOYSA-N
assay
99%
form
foil
manufacturer/tradename
Goodfellow 136-091-11
resistivity
54 μΩ-cm
size × thickness
25 x 25 mm × 0.125 mm
bp
3464 °C (lit.)
mp
920 °C (lit.)
density
6.19 g/mL at 25 °C (lit.)
Looking for similar products? Visit Product Comparison Guide
General description
For updated SDS information please visit www.goodfellow.com.
Legal Information
Product of Goodfellow
Storage Class
4.3 - Hazardous materials which set free flammable gases upon contact with water
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Marc E De Broe
Seminars in dialysis, 21(2), 142-144 (2008-02-06)
The recent recognition of gadolinium (Gd) administration as a cause of nephrogenic systemic fibrosis (NSF) is a growing concern. The similarity of Gd and lanthanum (La), based on their place in the table of Mendeljev, has led to assumptions that
Declan de Freitas et al.
Seminars in dialysis, 20(4), 325-328 (2007-07-20)
Hyperphosphatemia is associated with increased morbidity and mortality in dialysis patients. Oral phosphate binders are necessary to control serum phosphate in patients eating a normal diet and undergoing peritoneal dialysis or thrice weekly hemodialysis. Until recently, none of the available
Mario Cozzolino et al.
Expert opinion on pharmacotherapy, 13(16), 2337-2353 (2012-10-05)
High phosphate levels are associated with unfavorable outcomes in ESRD. Recent data suggested that phosphate levels within the normal range are equally associated with poor outcomes in the community and CKD stage 3 - 4. Several concept papers support the
Stephen J P Damment et al.
Clinical pharmacokinetics, 47(9), 553-563 (2008-08-14)
Lanthanum carbonate is considered to be the most potent of a new generation of noncalcium phosphate binders used to treat hyperphosphataemia in chronic kidney disease (CKD), a condition associated with progressive bone and cardiovascular pathology and a markedly elevated risk
Amy Barton Pai et al.
Expert opinion on drug metabolism & toxicology, 5(1), 71-81 (2009-02-25)
Hyperphosphatemia is recognized as a principal mineral disorder in chronic kidney disease (CKD) that leads to the development of secondary hyperparathyroidism. Recent data indicate that hyperphosphatemia is associated with accelerated cardiac calcification and increased mortality in patients with CKD. Control
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service